ArticleOphthalmology and therapy2025
Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between central serous chorioretinopathy and personality types: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review.Frontiers in medicine · 2025Pooled it
- Photodynamic Therapy in Central Serous Chorioretinopathy: Treatment Timing, Anatomical Response, and Recurrence in a Large Real-World Cohort.Ophthalmology and therapy · 2026Article
- Steroid-Induced Central Serous Chorioretinopathy in Uveitis: Diagnostic Challenges and Multimodal Imaging with a Primary Inflammatory Choriocapillaropathy Illustrative Case.Diagnostics (Basel, Switzerland) · 2026Article
- Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy.Journal of clinical medicine · 2026Article
- Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCentral serous chorioretinopathy (CSC) is a prevalent exudative maculopathy; however, exact details of its incidence and a global estimate of its annual incidence are lacking. It is paramount to understand the details of the incidence of CSC when discussing its societal and personal impact, the impact of medicine shortages and initiatives for healthcare policies, and organization of retinal service.
methodsIn this study, we systematically reviewed the literature on the incidence of CSC and performed meta-analyses to provide an age-stratified estimate of its incidence. By using population statistics from the United Nations Population Division, we were able to estimate the global and country-specific incidence of CSC in 2025 and forecast until 2050.
resultsSeven eligible studies included a total of 324,954 new patients with CSC during their time of investigation. The summary estimate incidence rates per 100,000 person-years were 47.8 (95% confidence interval [CI] 31.7-61.7) for individuals 30-39 years, 71.8 (95% CI 41.7-109.7) for individuals 40-49 years, 58.5 (95% CI 29.9-96.1) for individuals 50-59 years, and 36.2 (95% CI 16.8-62.6) for individuals 60-69 years. We confirmed male sex as a risk factor (odds ratio 2.73, P < 0.0001), and found that male individuals were significantly younger than female individuals at onset of CSC (average difference of 3.30 years, P < 0.0001). We estimated that in 2025, 1.97 million individuals globally will develop CSC, and that the incidence will increase to 2.03 million individuals in 2030, 2.30 million individuals in 2040, and 2.43 million individuals in 2050. The CSC incidence peaked between 40 and 49 years underscoring the significance in working-age individuals.
conclusionNumbers presented in this study highlight that CSC is one of the more prevalent maculopathies in our world and underscores the importance of education, research, and healthcare planning related to CSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.